Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 2/20 | 0.42 |
| ▸ | LSS | P48449 | 4/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | ESRRG | P62508 | 1/20 | 0.37 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
| ▸ | CYBB | P04839 | 1/20 | 0.34 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4089112 | 0.85 | PTPN1 (0.40) | LSSNR1H2NR1H3HTR7KIF11 | |
| SCHEMBL19865673 | 0.85 | MAPT (0.45) | MLYCDNR1H2NR1H3KIF11 | |
| SCHEMBL19823011 | 0.84 | MMP14 (0.43) | NR1H2NR1H3KIF11ESRRGTMEM97 | |
| SCHEMBL13261444 | 0.83 | MAPT (0.46) | MLYCDNR1H2NR1H3KIF11TLR8 | |
| SCHEMBL7981775 | 0.81 | HTR7 (0.52) | HTR7TLR8 | |
| SCHEMBL15362902 | 0.81 | MAPT (0.51) | MLYCDNR1H2NR1H3KIF11 | |
| SCHEMBL5539693 | 0.79 | KIF11 (0.39) | NR1H2NR1H3KIF11TMEM97SIGMAR1 | |
| SCHEMBL13223821 | 0.79 | SLC6A4 (0.37) | MLYCDNR1H2NR1H3KIF11 | |
| SCHEMBL13724651 | 0.78 | NR1H2 (0.44) | LSSNR1H2NR1H3KIF11 | |
| SCHEMBL19822977 | 0.78 | SLC9A5 (0.40) | MLYCDNR1H2NR1H3KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090197201-A1 | FLUOROSURFACTANTS | MERCK PATENT GESELLSCHAFT (DE) | 2009-08-06 | — | — | US | disclosed |
| EP-2035129-A1 | FLUOROSURFACTANTS | Merck Patent GmbH (DE) | 2009-03-18 | — | — | EP | disclosed |
| WO-2008003443-A1 | FLUOROSURFACTANTS | MERCK PATENT GMBH (DE) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197201-A1 | FLUOROSURFACTANTS | CBR3, SCO2, FPR3 | MLYCD 2657/4885LSS 909/4885NR1H2 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.